氨磷汀对化疗中造血干/祖细胞的保护作用

Protective Effects of Amifostine on Hematopoietic Stem/Progenitor Cells Against Chemotherapeutic Damage

为了评估氨磷汀 (amifostine ,AMF)在保护正常造血干 /祖细胞免受化疗药物依托泊甙 (etoposide ,VP 16)损伤方面的作用 ,将脐血单个核细胞 (CBMNC)、新鲜和冻存的外周血造血干细胞 (PBSC)和HL 60细胞 ,分别分为AMF +VP 16组、VP 16组、AMF组和空白对照组 ,用台盼蓝拒染法检测细胞活性 ,CFU GM集落培养计数 ,流式细胞术 (FCM)测定细胞的凋亡率。结果显示 :在CBMNC、新鲜和冻存的PBSC样本中 ,AMF +VP 16组的存活率和集落形成能力较VP 16组显著提高 (P <0 .0 5 ) ;在CBMNC样本中 ,3种浓度的AMF组的集落形成能力与对照组的差异无统计学意义 (P >0 .0 5 ) ;在HL 60细胞的样本中 ,AMF +VP 16组与VP 16组凋亡率的差异无统计学意义 (P >0 .0 5 )。结论 :AMF能保护正常造血干 /祖细胞免受化疗药物VP 16的损伤 ,并且不影响VP 16对HL 60细胞的杀伤效果 ,但是AMF不能直接促进脐血造血干 /祖细胞的生长和分化。

The aim was to study the protective effects of amifostine (AMF) on normal hematopoietic stem/progenitor cells against the chemotheraputic damage from etoposide (VP 16). The cord blood mononuclear cells (CBMNC), fresh and frozen peripheral blood stem cells (PBSC), and HL 60 cells were divided into AMF, AMF+VP 16, VP 16 and control groups, each group cell viability was determined by using trypan blue exclusion test, the CFU GM culture was used to count cells, the apoptosis was detected by flow cytometry. The results showed that in CBMNC, fresh and frozen PBSC samples, cell viability and the number of CFU GM in AMF+VP 16 group were all significantly higher than those in VP 16 group ( P < 0.05); the CFU GM incidence in AMF+VP 16 group was higher than that in VP 16 group, and the GFU GM life in AMF+VP 16 group was also longer than that of latter, in CBMNC samples, the number of CFU GM in AMF groups was higher than that in control group, but there was no statistical significance between the two groups ( P > 0.05), in HL 60 cell apoptotic rate in AMF+VP 16 group was little higher than that in VP 16 group, but no statistical significance between these two groups ( P > 0.05). It is concluded that AMF can significantly protect normal hematopoietic stem/progenitor cells against the damage from VP 16. Moreover, AMF does not affect cytotoxity of VP 16 on HL 60 cells, and can not stimulate the growth and differentiation of cord hematopoietic stem/progenitor cells directly.